BACKGROUND: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients with advanced colorectal cancer (aCRC) have reported conflicting results. METHODS: A systematic review of RCTs comparing standard treatments±anti-EGFR MAbs was conducted. Hazard ratios (HR) for progression-free (PFS) and overall survival (OS) were derived for patients with wild-type (WT) and mutant KRAS. Prespecified analyses were conducted for line of treatment, MAb used, chemotherapy regimen...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
If you are the owner of this record, you can report an update to it here: Report update to this record